Normal tonsil
BCL2 Oncoprotein (Dako Omnis)
IVD
For In Vitro Diagnostic Use.
- Monoclonal Mouse Anti-Human
No data to display
This product is not available for purchase by the general public.
Product Details
Features
- Optimized staining performance of both high and low-expression structures
- Crisp and clear staining with no background
- Optimal laboratory efficiency with ready-to-use antibodies on Dako Omnis family of instruments
- Consistent, uniform staining with excellent morphology enabled by dynamic gap staining technology on the Dako Omnis family of instruments
- Defined, tested, and approved staining performance for all FLEX RTU antibodies through collaboration with leading international pathology experts
Specifications
| Application |
|
| Clone |
|
| Code Number |
|
| Form/Configuration |
|
| Immunogen |
|
| Isotype |
|
| Reagent Provided |
|
| Solutions |
|
| Specialty |
|
| Species |
|
| Specificity |
|
Literature
- Catalogs
-
Atlas of Controls
The Atlas of Controls illustrates the staining performance of each antibody in the FLEX Ready-to-Use system.
- Catalogs
- English
- 31 Jul 2026
- 37.96 MB
- Technical Overviews
Support
- Instructions for Use
-
Featured References
- Product Description References
-
1.Yang, E.; Korsmeyer, S. J. Molecular Thanatopsis: A Discourse on the BCL2 Family and Cell Death. Blood 1996, 88 (2), 386–401. DOI: 10.1182/blood.V88.2.386.bloodjournal882386.
2.Lešková, K.; Szépe, P.; Balhárek, T.; Barthová, M.; Janáková, Ľ.; Farkašová, A.; Plank, L. High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements: Biopsy Analysis of 70 Cases from the Slovak Lymphoma Registry. Neoplasma 2022, 69 (4), 957–964. DOI: 10.4149/neo_2022_220318N300.
3.Pătraşcu, A.-M.; Rotaru, I.; Olar, L.; Pătraşcu, Ş.; Ghiluşi, M.-C.; Neamţu, S.-D.; Nacea, J.-G.; Gluhovschi, A. The Prognostic Role of Bcl-2, Ki67, c-MYC and p53 in Diffuse Large B-Cell Lymphoma. Rom. J. Morphol. Embryol. 2017, 58 (3), 837–843.
4.Hoeller, S.; Bihl, M. P.; Zihler, D.; Cogliatti, S.; Ponzoni, M.; Zettl, A.; Went, P.; Foerster, A.; Hirschmann, P.; Tzankov, A.; et al. Molecular and Immunohistochemical Characterization of B-Cell Lymphoma-2–Negative Follicular Lymphomas. Hum. Pathol. 2012, 43 (3), 405–412. DOI: 10.1016/j.humpath.2011.05.018.
5.Boltežar, L.; Prevodnik, V. K.; Perme, M. P.; Gašljević, G.; Novaković, B. J. Comparison of the Algorithms Classifying the ABC and GCB Subtypes in Diffuse Large B-Cell Lymphoma. Oncol. Lett. 2018, 15 (5), 6903–6912. DOI: 10.3892/ol.2018.8243.
6.Chao, C.; Silverberg, M. J.; Martínez-Maza, O.; Chi, M.; Abrams, D. I.; Haque, R.; Zha, H. D.; McGuire, M.; Xu, L.; Said, J. Epstein–Barr Virus Infection and Expression of B-Cell Oncogenic Markers in HIV-Related Diffuse Large B-Cell Lymphoma. Clin. Cancer Res. 2012, 18 (17), 4702–4712. DOI: 10.1158/1078-0432.CCR-11-3169.
7.Wu, C.-H.; Gau, J.-P.; Teng, C.-L. J.; Shih, Y.-H.; Su, Y.-C.; Wang, R.-C.; Chen, T.-C. Clinical Features and Immunophenotypes of Double-Hit Diffuse Large B-Cell Lymphoma. Diagnostics 2022, 12 (5), 1106. DOI: 10.3390/diagnostics12051106.
8.Yuan, J.; Liu, H.; Hu, S.; Miranda, R. N.; Xu, X.; Bayerl, M. G.; Artymiuk, C. J.; Berg, H.; King, R. L.; Shi, M.; et al. Follicular Lymphoma and Diffuse Large B-Cell Lymphoma with BCL2 and IRF4 Rearrangements in Adult Patients. Hum. Pathol. 2023, 141, 22–29. DOI: 10.1016/j.humpath.2023.08.008.
9.Abdelrahim, L. M.; Peh, S.-C.; Kallarakkal, T. G. Epstein–Barr Virus Infection in B-Cell Non-Hodgkin’s Lymphomas of the Oral and Maxillofacial Region: Is There Any Evidence? Malays. J. Pathol. 2018, 40 (1), 49–56.
10.Choe, J.-Y.; Park, M.; Yun, J. Y.; Na, H. Y.; Go, H.; Kim, H.-J.; Oh, S.; Kim, J. E. PELI1 Expression Is Correlated with MYC and BCL6 Expression and Associated with Poor Prognosis in Diffuse Large B-Cell Lymphoma. Mod. Pathol. 2016, 29 (11), 1313–1323. DOI: 10.1038/modpathol.2016.128.
11.Caramuta, S.; Lee, L.; Özata, D. M.; Akçakaya, P.; Georgii-Hemming, P.; Xie, H.; Amini, R.-M.; Lawrie, C. H.; Enblad, G.; Larsson, C.; et al. Role of microRNAs and MicroRNA Machinery in the Pathogenesis of Diffuse Large B-Cell Lymphoma. Blood Cancer J. 2013, 3, e152. DOI: 10.1038/bcj.2013.49.
12.Na, H. Y.; Choe, J.-Y.; Shin, S. A.; Kim, H.-J.; Han, J. H.; Kim, H. K.; Oh, S. H.; Kim, J. E. Characteristics of CD5-Positive Diffuse Large B-Cell Lymphoma among Koreans: High Incidence of BCL2 and MYC Double-Expressors. PLoS One 2019, 14 (10), e0224247. DOI: 10.1371/journal.pone.0224247.
13.Chiche, J.; Reverso-Meinietti, J.; Mouchotte, A.; Rubio-Patiño, C.; Mhaidly, R.; Villa, E.; Bossowski, J. P.; Proics, E.; Grima-Reyes, M.; Paquet, A.; et al. GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors. Cell Metab. 2019, 29 (6), 1243–1257.e10. DOI: 10.1016/j.cmet.2019.02.002.
14.Mao, X.; Orchard, G.; Lillington, D. M.; Child, F. J.; Vonderheid, E. C.; Nowell, P. C.; Bagot, M.; Bensussan, A.; Russell-Jones, R.; Young, B. D.; et al. BCL2 and JUNB Abnormalities in Primary Cutaneous Lymphomas. Br. J. Dermatol. 2004, 151 (3), 546–556. DOI: 10.1111/j.1365-2133.2004.06106.x.
15.Obermann, E. C.; Csato, M.; Dirnhofer, S.; Tzankov, A. BCL2 Gene Aberration as an IPI-Independent Marker for Poor Outcome in Non-Germinal-Centre Diffuse Large B-Cell Lymphoma. J. Clin. Pathol. 2009, 62 (10), 903–907. DOI: 10.1136/jcp.2009.066597.
16.Wang, J.; Hasui, K.; Jia, X.; Matsuyama, T.; Eizuru, Y. Possible Role for External Environmental Stimuli in Nasopharyngeal NK/T-Cell Lymphomas in the Northeast of China with EBV Infection-Related Autophagic Cell Death: A Pathoepidemiological Analysis. J. Clin. Exp. Hematopathol. 2009, 49 (2), 97–108. DOI: 10.3960/jslrt.49.97.
17.Rossi, A.; Mazzara, S.; Salemi, D.; Zanetti, S.; Sapienza, M. R.; Orecchioni, S.; Talarico, G.; Falvo, P.; Davini, A.; Ceccarelli, C.; et al. Downregulation of rRNA Synthesis by BCL-2 Induces Chemoresistance in Diffuse Large B Cell Lymphoma. iScience 2025, 28 (5), 112333. DOI: 10.1016/j.isci.2025.112333.
18.Hoeller, S.; Tzankov, A.; Pileri, S. A.; Went, P.; Dirnhofer, S. Epstein–Barr Virus–Positive Diffuse Large B-Cell Lymphoma in Elderly Patients Is Rare in Western Populations. Hum. Pathol. 2010, 41 (3), 352–357. DOI: 10.1016/j.humpath.2009.07.024.
19.van Zwieten, A. Tissue Microarray Technology and Findings for Diagnostic Immunohistochemistry. Pathology 2013, 45 (1), 71–79. DOI: 10.1097/PAT.0b013e32835b7b99.
Related Products
Promotions